Ruiwu Liu, Ph.D.
Oak Park Research Building, Suite 2301
Sacramento, CA 95817
Ph: 916-734-6414

Dr. Liu’s research includes developing new methods for combinatorial chemistry and high throughput screening, and applying these powerful technologies to drug discovery. His current research focuses on 1) developing cancer-targeting imaging and therapeutic agents for prostate cancer, ovarian cancer, lymphoma and glioblastoma; 2) discovery of small molecule anticancer drugs from combinatorial libraries; 3) developing peptide-drug conjugates (PDC) and antibody-drug conjugates (ADC) for cancer therapy; 4) developing novel targeted nanodrugs for cancer therapy.

Liu R, Li C, Xiao W, Lam KS. Tumor-targeting peptides from combinatorial libraries. Adv Drug Deliver Rev, May 19, 2016, Epub ahead of print. doi:10.1016/j.addr.2016.05.009.

Yao W, Lay YE, Kot A, Liu R, Zhang H, Chen H, Lam K, Lane NE. Improved mobilization of exogenous mesenchymal stem cells to bone for fracture healing and sex difference. Stem Cells. 2016;34:2587-2600

Xiao W, Li T, Bononi FC, Lac D, Kekessie IA, Liu Y, Sanchez E, Mazloom A, Ma A-H, Lin J, Tran J, Yang K, Lam KS, Liu R. Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of α3 integrin-expressing human tumors. EJNMMI Res, 2016, 6:18

Lac D, Feng S, Bhardwaj G, Le H, Tran J, Xing L, Fung G, Liu R, Cheng H, Lam KS. Covalent chemical ligation strategy for mono- and polyclonal immunoglobulins at their nucleotide binding sites. Bioconjugate Chem, 2016, 27: 159−169.

Leung N, Wai C, Ho M, Liu R, Lam KS, Wang J, Shu SA, Chu KH, Leung P. Screening and identification of mimotopes of the major shrimp allergen Tropomyosin using one bead one compound peptide libraries. Cell Mol Immunol, Sept 14, 2015, Epub ahead of print, doi:10.1038/cmi.2015.

Guo W, Liu R, Bhardwaj G, Yang JC, Changou C, Ma A-H, Mazloom A, Chintapalli S, Xiao K, Xiao W, Kumaresan P, Sanchez E, Yeh C-T, Evans CP, Patterson R, Lam KS and Kung H-J. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis, 2014, 5: e1409.

Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX. Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. Nanomedicine, 2014, 9: 1807-1820.

Liu R, Wettersten H, Park S-H, Weiss RH. Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer. Future Med Chem, 2013, 5: 991-994.

Guo W, Liu R, Bhardwaj G, Ma AH, Changou C, Yang JC, Li Y, Feng C, Luo Y, Mazloom A, Sanchez E, Wang Y, Huang W, Patterson R, Evans CP, Lam KS, Kung H-J. CTA095, a Novel Etk and Src Dual Inhibitor, Induces Apoptosis in Prostate Cancer Cells and Overcomes Resistance to Src Inhibitors. PLoS One, 2013, 8: e70910.

Yao W, Guan M, Jia J, Dai W, Lay YA, Amugongo S, Liu R, Olivos D, Saunders M, Lam K, Nolta J, Olvera D, Ritchie RO, Lane NE. Reversing Bone Loss by Directing Mesenchymal Stem Cells to the Bone. Stem Cells, 2013, 31: 2003-2014

Guo W, Liu R, Ono Y, Ma A-H, Martinez A, Sanchez E, Wang Y, Huang W, Mazloom A, Li J, Ning J, Maverakis E, Lam KS, Kung H-J. Molecular Characteristics of CTA056, a Novel Interleukin-2-Inducible T-Cell Kinase Inhibitor that Selectively Targets Malignant T Cells and Modulates Oncomirs. Mol Pharmacol, 2012, 82: 938-947.

Guan M, Yao W, Liu R, Lam KS, Nolta J, Jia J, Panganiban B, Meng L, Zhou P, Shahnazari M, Ritchie RO, Lane NE. Directing mesenchymal stem cells to bone to argument bone formation and increase bone mass. Nat Med, 2012, 18(3): 456-462.

DeNardo SJ, Liu R, Albrecht H, Natarajan A, Sutcliffe JL, Anderson C, Peng L, Ferdani R, Cherry SR, Lam KS. 111In-LLP2A-DOTA polyethylene glycol-targeting α4β1 integrin: Comparative pharmacokinetics for imaging and therapy of lymphoid malignancies. J Nuclear Med, 2009, 50(4): 625-634.

Peng L, Liu R, Andrei M, Xiao W, Lam KS. In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against alpha4 beta1 integrin. Mol Cancer Ther 2008, 7: 432-437.

Aina OH, Liu R, Sutcliffe JL, Marik J, Pan C., Lam KS. From combinatorial chemistry to cancer targeting peptides. Mol Pharm 2007, 4: 631-651.

Dixon SM, Li P, Liu R, Wolosker H, Lam KS, Kurth MJ, Toney MD. Slow-binding human serine racemase inhibitors from high-throughput screening of combinatorial libraries. J Med Chem, 2007, 49: 2388-2397.

Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. Combinatorial chemistry identifies high-affinity peptidomimetics against a4b1 integrin for in vivo tumor imaging. Nat Chem Biol 2006, 2: 381-389.

Lam KS, Liu R, Miyamoto S, Lehman AL, Tuscano JM. Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research. Acc Chem Res, 2003, 36: 370-377.

Liu R, Enstrom AM, Lam KS. Combinatorial peptide library methods for immunobiology research. Exp Hematol 2003; 31: 11-30.

Liu R, Marik J, Lam KS. A novel peptide-based encoding system for "one-bead one-compound" peptidomimetic and small molecule combinatorial libraries. J Am Chem Soc 2002, 124: 7678-7680.